Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study - The Lancet Haematology #mmsm ⁦Dana-Farber⁩ ⁦Promise Study⁩ thelancet.com/journals/lanha…

Super excited to share our work out in The Lancet Haematology Fantastic effort lead by 🌟 Annie improving on predicting risk of progression in patients with MGUS / SMM using data from around the 🌎 Don’t miss the user- friendly app ⬇️ Ghobrial Lab Dana-Farber News .

So proud of you ❤️

This is an excellent group with incredible experience in an important but understudied topic. If you are an AYA with cancer and fit please consider reaching out! #AYACSM

Ending a fantastic time Ghobrial Lab Dana-Farber working with some of the most dedicated scientists and physicians. Thank you . for all your support and mentorship. Can’t wait for the team’s next achievements!

Alexandre Maalouf loves to talk about the role of B cells and TLS in rhabdomyosarcoma! great poster!! #pediatricsarcoma Johns Hopkins Kimmel Cancer Center @bloombergkimmel

High-Throughput Plasma Proteomics to Define the Precursor Multiple Myeloma Proteome and Identify Candidate High-Risk Disease Biomarkers of Progression [Sat, Dec 9, 2023: 4:45p] Lightbody et al. Irene Ghobrial #ASH23 Abst 334 ash.confex.com/ash/2023/webpr… #mmsm #caxtx

In contrast to our previous study of #CHIP in #multiplemyeloma which was in a different era, we now report good outcomes even in those with #myeloma and #CHIP in the era of novel agents. Yet, there is an accelerated increase in the incidence of CHIP while on #mmsm treatment.

Stay tuned for more on this exciting work from Ghobrial Lab !

Congratulations to Kate Shimamoto Habib El-Khoury, MD and Ethan Harris for their ASH #ASH24 Abstract Achievement Awards! Saygin Lab has some cool science to present in San Diego!

Huge congratulations to Kate Shimamoto, Habib El-Khoury, MD, and Ethan Harris 🎉

#ASH24 #mmsm 2️⃣ PANGEA- 2 model to predict progression of smoldering myeloma ➡️ ash.confex.com/ash/2024/webpr… ✅n=1431, longitudinal data on age, M-protein, FLCr, creatinine, and hemoglobin,BM PC (optional) ✅median F/U: 3.5 years, only 19% progressed to MM Dynamic model

Off to San Diego from 24h in the PICU ➡️ #ASH24 Thanks to Caner Saygin, MD ‘s mentorship, we will be presenting our work with an abstract achievement award. CH landscape and clinical correlates in AYA survivors of childhood ALL UChicagoMedPeds

#ASH24 #mmsm ASH Oral myeloma: Evolution of Clonal Hematopoiesis after Discontinuation of Therapy for Multiple Myeloma High prevelande of clonal hematopoesis after induction and auto transplant TP53 mutant clones expand with Revlamid maintenance Ben Derman

Join us this afternoon at #ASH24 for an outstanding lineup of poster presentations! Don't miss to explore the developments from UChicagoCancerCenter faculty and trainees. University of Chicago Hematology/Oncology UChicago Leukemia Program

At #ASH24, Habib El-Khoury presents cool poster looking at the clonal hematopoiesis landscape in younger ALL survivors to predict the future cytotoxic treatment related health complications. Caner Saygin, MD Habib El-Khoury, MD University of Chicago Hematology/Oncology UChicago Leukemia Program

Sabine presenting her data on the long term follow up of MGIP and MGUS to MM in the PLCO cohort. Clonal competition between monoclonal spikes! #ash24 #mmsm

Looking for a cardiology career? Cardiac Amyloidosis Program seeking candidates for 1 year post-doctoral fellowship at Columbia Medicine. Training in multidisciplinary research and team-based care with CUIMC depts and other centers of excellence throughout US and abroad.